There is now a rich pipeline of novel agents in clinical trials for the treatment of patients with multiple myeloma. At the 20th Congress of the European Hematology Association (EHA), Pieter Sonneveld, MD, of the Erasmus MC University Cancer Institute, Rotterdam, the Netherlands, discusses the impact of these novel agents in current treatment practices for multiple myeloma.